Skip to main content

The Oncology Pharmacist® features articles written by and for oncology pharmacists and specifically addresses the issues pharmacists and their colleagues face every day in clinical practice.

Featured Articles

  • BEST PRACTICES
  • HEALTHCARE EQUITY
  • BIOMARKERS

Featured Video

Who Are the Patients with Multiple Myeloma Who May Not Adhere to Their Treatment Regimen?

Charise Gleason, MSN, NP-C, AOCNP, and Nikki Barkett, RN, BSN, OCN, talk about the clues and the patient characteristics that they use to determine which of their patients with multiple myeloma may be at risk for not adhering to their anticancer therapy.

OCTOBER SPOTLIGHT

  • October is Breast Cancer Awareness Month. Take our quiz and explore our articles to stay up to date on prostate cancer.

    Quick Quiz View Breast Cancer Articles
  • Breast Cancer

    According to the American Cancer Society, approximately 353,510 new cases of breast cancer (297,790 cases of invasive breast cancer and 55,720 cases of ductal carcinoma in situ) will be diagnosed in women in the United States in 2023, and approximately 43,700 women will die from the disease. How much do you know about Breast Cancer?

  • Adding Ribociclib to Endocrine Therapy May Reduce Risk for Recurrence in HR-Positive, HER2-Negative, Early Breast Cancer

    Chicago, IL—The addition of the CDK4/6 inhibitor ribociclib (Kisqali) to endocrine therapy significantly improved invasive disease-free survival in patients with hormone receptor (HR)-positive, HER2-negative, early breast cancer, according to interim results of the phase 3 NATALEE trial, which were presented at the 2023 American Society of Clinical Oncology Annual Meeting.